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Reproductive Environment in 
Patients with SLE
María del Carmen Zamora-Medina and Juanita Romero-Díaz
Abstract
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disorder 
that predominantly affects women in reproductive years. Immunologic and hor-
monal adaptations during pregnancy focused on creating an ideal environment 
to achieve a successful pregnancy represent a challenge in SLE women as they can 
influence on disease activity and outcomes during pregnancy. Several disease-
related factors such as the presence of antiphospholipid antibodies and anti-SSA/Ro 
can also impact in the risk of pregnancy adverse outcomes and neonatal complica-
tions. Lupus nephritis and preeclampsia share clinical and laboratory features hin-
dering differentiation between both entities. Contraception constitutes a relevant 
topic in SLE patients to prevent unplanned pregnancies during periods of disease 
activity or potentially teratogenic drug exposure, but its potential risk on disease 
flares and thrombotic events is the main concern. Finally, fertility in patients with 
SLE can be affected by the use of drugs related to infertility that lead to premature 
ovarian failure. Recently, assisted reproduction technologies have emerged as a safe 
option in patients with SLE.
Keywords: systemic lupus erythematosus, pregnancy, pregnancy adverse outcomes, 
neonatal lupus, contraception, antiphospholipid antibodies, anti-SSA/Ro
1. Introduction
Systemic lupus erythematosus (SLE) is a chronic multisystemic autoimmune 
disease, with a remitting and relapsing course. It mainly affects young women of 
reproductive age, so addressing issues such as pregnancy, fertility, and reproductive 
aspects is an essential part of the comprehensive management of these patients.
In the last decades, diagnostic and therapeutic strategies for SLE and conse-
quently the management of pregnancy have improved. Despite these advances, 
pregnancies in SLE patients are still considered a high-risk condition due to an 
increased risk of major obstetrical and neonatal complications.
Pregnancy represents a critical period in women’s life due to profound immuno-
logical and hormonal changes that mostly occur to tolerate the fetus. The interac-
tion of SLE and immunologic adaptations of pregnancy lead to unique challenges 
in this setting, as alterations in immune mechanisms can have consequences both 
for the fetus, including a risk of miscarriage or neonatal lupus, and for the mother, 
including disease flare.
A close relationship between pregnancy and disease flares has been established. 
The association of SLE and pregnancy, mainly with active disease and lupus nephri-
tis, has poorer outcomes, with increased frequency of preeclampsia (PE), fetal loss, 
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preterm birth, and intrauterine growth restriction. On the other hand, pregnancy 
impacts on maternal disease and can be associated with disease flares requiring 
immunosuppressive therapy.
This chapter will address the immunological and hormonal adaptations dur-
ing normal pregnancy and the differences between healthy pregnant women and 
women with SLE. Later, we will focus on the relationship between lupus activity 
and pregnancy and the impact of SLE on pregnancy outcomes.
2. Interaction between pregnancy and systemic lupus erythematosus
2.1 Immunologic and neuroendocrine environment in pregnancy
Pregnancy represents a major immunological challenge for the maternal body 
due to fetal expression of paternal antigens. The maternal immune system has to 
balance the opposing needs of maintaining robust immune reactivity to protect 
both the mother and the fetus from invading pathogens while at the same time 
tolerating highly immunogenic paternal alloantigens to sustain fetal integrity [1].
In order to protect the fetus from an attack of the maternal immune system, 
pregnancy induces profound immune and neuroendocrine changes in the maternal 
body [2]. Modulation of the function and composition of the different cellular com-
ponents and immunomodulatory molecules occur during pregnancy in the mother. 
Also, immune tolerance to paternal antigens is promoted by migration of fetal cells 
and cell-free DNA to the maternal circulation during pregnancy, which can remain 
with the mother for decades [3].
During pregnancy, a shift of cytokine profile toward a T-helper 2 (Th2) response 
instead of Th1 was considered one of the most important immunological modi-
fications. Suppression of Th CD4+ cells (Th1 response) in uncomplicated human 
pregnancy and Th1 polarization in patients with reproductive failure has supported 
the concept of successful pregnancy as a Th2 phenomenon proposed by Wegmann [4]. 
However, recent extensive research on the physiology of pregnancy has shown that 
the hypothesis that pregnancy is warranted by Th1/Th2 shift is simplistic [5].
During the different stages of pregnancy, cytokine production at the feto-
maternal interface is regulated to create optimal conditions for fetal development. 
Interferon (IFN)-γ and TNF-α, both cytokines secreted by Th1 cells and major con-
tributors to Th1 immune response, are necessary during early stages of pregnancy 
for successful implantation and placenta development but later in pregnancy could 
be detrimental and result in pregnancy loss [2]. Chorionic villous tissue expresses 
not only Th2-type cytokines but also IL-1 β and TNF-α in the first trimester [6]. On 
the other hand, high expression of IL-10, a pleiotropic cytokine with both immune 
stimulatory and immune suppressive functions, is present in the human placenta at 
term [7].
In line with local cytokine modulation and as a reflection of systemic effects of 
pregnancy, cytokine secretion in peripheral blood mononuclear cells (PBMC) changes 
during pregnancy. In vitro assays from whole blood of healthy pregnant women have 
shown a diminished pro-inflammatory response, with a decrease of TNF-α, IL-1β, 
and IL-6, while IL-4 and IL-10 remain stable during pregnancy [8]. During the third 
trimester, a reduction of IL-12 and TNF-α production was detected in monocytes from 
healthy pregnant women compared to postpartum values [9]. An increase of IL-4-
secreting PBMC, but not of IFN-γ-positive cells, was found in the second and third 
trimesters of pregnancy in healthy women after stimulation with paternal antigens 
[10]. The same group found significantly higher numbers of IFN-γ- and IL-4-secreting 
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PBMC in all three trimesters of pregnancy and also postpartum than the nonpreg-
nant controls, indicating a systemic upregulation of both Th1- and Th2-like immune 
responses during normal pregnancy [11].
Besides cytokines, regulatory molecules that modify cytokine actions such as IL-1Ra 
and IL-6R have been found to be increased in serum of pregnant women, as well as 
levels of IL-6 and IL-1. Likewise, levels of soluble TNFR were found significantly 
increased in the second and third trimesters of pregnancy compared to nonpregnant 
values [3]. Thereby, both Th1- and Th2-type cytokines are important players of immune 
adaptation to pregnancy at local and systemic levels. Its production is adjusted to the 
different stages of pregnancy and, in addition with upregulation of cytokine-regulating 
molecules, can exert an ideal environment to achieve a successful pregnancy.
Pregnancy also induces substantial changes in hormone levels, which have pow-
erful effects on blood cells as they can regulate their proliferation, distribution, and 
function. Estrogens enhance antibody production, Th2-type immune responses, 
and B-cell immunity [7]. At high concentrations, such as those found in pregnancy, 
estrogens and gestagens stimulate the secretion of IL-4, IL-10, TGF-𝛽, and IFN-𝛾 
while simultaneously suppressing production of TNF-α [3, 12].
Therefore, pregnancy influences the interaction between neuroendocrine and 
immune systems both locally and systemically with a fine balance that creates optimal, 
but not uniform conditions at the feto-maternal interface and in the maternal circulation.
2.2 Maternal tolerance to the fetus in normal pregnancy
Although localized mechanisms at the maternal-fetal interface contribute to 
fetal evasion from an immune attack, several additional mechanisms operate during 
pregnancy and help the fetus to evade maternal immune response.
In this context, regulatory T (Treg) cells have been shown to play a pivotal role 
in maternal-fetal tolerance. These Treg cells, a subset of suppressor CD4+ CD25+ 
cells, play a dominant role in the maintenance of immunological self-tolerance by 
preventing immune and autoimmune responses against self-antigens. In recent 
years, it has been observed that Treg cells are essential in promoting fetal survival, 
avoiding the recognition of paternal semi-allogeneic tissues by maternal immune 
system, a critical step for successful pregnancy [13, 14].
In healthy pregnant women, CD4+ CD25+ Treg increases rapidly in peripheral 
blood peaking at midgestation coinciding with the time of maximal trophoblast 
invasion and decreasing after delivery to prepregnancy levels [15]. Levels of Treg 
cells within the decidua, which represents the maternal-fetal interface, are elevated 
compared with those in the peripheral blood. The increase in Treg cells emphasizes 
the potential role for these cells in the successful development of the placenta by 
ensuring fetal tolerance [16].
Expansion of Treg cells is not only due to hormonal changes occurring during 
pregnancy, but can be driven by several other factors like decidual peptides, fetal 
antigens, and seminal fluid. Indeed, Treg cells act in an antigen-specific manner as they 
are specifically activated by MHC paternal antigens, but once activated they are able to 
exert suppressive effects on other local cells in an antigen-independent manner [16, 17].
The exact mechanism by which Treg cells exert their suppressive activity during 
pregnancy is not completely clear but is likely to be mediated by cell contact-
dependent and cell contact-independent manipulations of dendritic cells (DCs) 
and effector Th cells, as well as direct cytolytic activity on DCs and modulation of 
the local metabolic environment [1, 17]. Recent data support the capacity of Tregs 
to block maternal effector T cells, thereby reducing the maternal-fetal pathological 
responses to paternal antigens [18].
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A prospective observational study of 101 women who underwent in vitro 
fertilization (IVF) showed an increased level of circulating Treg cells in pregnant 
women. A higher percentage of Treg in peripheral blood was associated with 
increased rates of pregnancy and live birth [19]. On the other hand, deficit in Treg 
cell number in the decidua and maternal peripheral blood has been associated with 
complications such as unexplained infertility, miscarriage, and preeclampsia [1, 13]. 
These observations support the Need for a substantial increase in Treg cell numbers 
for a successful pregnancy.
Interestingly, during pregnancy a bidirectional exchange of cells at the maternal-
fetal interface occurs, so maternal cells can cross the placenta and engraft in fetal 
lymph nodes in utero, a phenomenon called maternal microchimerism. Human 
fetal T cells are responsive against maternal alloantigen, but a pool of fetal Treg 
cells actively suppresses their function. Maternal microchimerism has been shown 
to induce development in utero of fetal Treg cells that suppress fetal antimaternal 
immune response, indicating a mechanism that promotes tolerance toward mater-
nal antigens by the fetus [14, 20].
Besides Th1 and Th2 cells, there is a third subset of CD4+ T-helper cells called Th17 
cells, which, like Treg cells, are implicated in pregnancy and maternal immune toler-
ance to the fetus [14]. These Th17 cells are defined by their ability to produce IL-17, a 
pro-inflammatory cytokine that promotes development of Th17 cells and interestingly, 
in the presence of a tolerance milieu, drives differentiation to Treg cells [21]. Both 
Treg and Th17 cells require transforming growth factor beta (TGF-β) for differentia-
tion, but the copresence of IL-6 favors differentiation of pathogenic Th17 cells as it 
can inhibit the generation of FoxP3+ in Treg cells induced by TGF-β [22]. Th17 cells 
promote inflammation and generally have opposing actions to Treg cells so a reciprocal 
relationship between these two subsets of Th cells has been described [21].
The presence of Th17 cells in human decidua of healthy pregnancies was investi-
gated. The first-trimester human decidua displayed a local expansion of Treg cells, 
while a low occurrence of Th17 cells was observed, which suggests that the inverse 
relationship between Treg and Th17 cells seems to be maintained at least in early 
stages of pregnancy [23].
On the other hand, increased numbers of Th17 have been found in obstetric 
complications such as preeclampsia and recurrent pregnancy loss (RPL). A signifi-
cant increase of Treg FoxP3+ to IL-17-expressing CD4+ T cell ratio in peripheral 
blood at the third trimester of healthy pregnancy was reported, while an absence of 
a reduction of IL-17 production toward a FoxP3+ expression was observed in pre-
eclamptic pregnancies [24]. In line with these observations, a later study reported 
an increased prevalence of IL-17-producing circulating T CD4+ and CD8+ cells in 
preeclampsia, demonstrating a shift in the Th17/Treg balance in this pregnancy 
complication [25].
Also, the proportion of Th17 cells in peripheral blood and decidua was signifi-
cantly higher in unexplained RPL patients compared to normal pregnant women. 
As reported in preeclamptic pregnancies, there was an inverse relationship between 
Th17 cells and Treg cells in peripheral blood and decidua in unexplained RSA [26]. 
Another study showed an accumulation of IL-17-producing cells in decidua of 
inevitable abortion cases compared to normal pregnancies and missed abortions [27]. 
Therefore, there is evidence suggesting that balance between Th17 cells and Treg 
cells may be critical to pregnancy outcomes.
2.3 SLE pregnancy vs. normal pregnancy
Differences in sex steroid hormones during pregnancy have been observed in 
patients with SLE compared to healthy women. In a prospective study, pregnant 
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lupus patients presented lower levels of estradiol and progesterone in the second 
and most of the third trimester of pregnancy [28]. The inability to produce high 
concentrations of these sex hormones during the last two trimesters of pregnancy 
could be due to placental insufficiency, which in turn can be implicated with the 
elevated rate of fetal loss in SLE patients [29].
Levels of certain cytokines involved in the humoral immune response have been 
shown to be modified in the peripheral circulation of pregnant SLE patients. Serum 
levels of IL-6, a cytokine necessary for T cell help for B cells and proliferation of 
plasma cells, are lower than expected in the third trimester of gestation. Higher 
levels of IL-10 before conception through pregnancy and postpartum in lupus 
patients compared to healthy controls have been observed, suggesting a consti-
tutional overproduction of IL-10 in SLE patients resulting in a continuous B-cell 
stimulation. Furthermore, levels of soluble TNF receptor I (sTNFR I) and IL-10 are 
significantly higher during pregnancy and postpartum in pregnant patients with 
active SLE compared to healthy controls [28].
Cytokine profile of PBMC in SLE and rheumatoid arthritis (RA) pregnant 
women was investigated in a prospective study by assessing cytokine messenger 
RNA (mRNA) expression using quantitative PCR. TNF-α was the most abundant 
cytokine mRNA expressed in PBMC in all three groups studied (healthy pregnant 
women, RA, and SLE pregnant patients). However, in RA and SLE patients, a 
general Th2 response reflected by high IL-10 levels was found [30].
Several studies have investigated the phenotype and function of Treg cells in 
patients with SLE. Most of the studies have shown a decrease in Treg cell numbers 
in SLE patients and a negative correlation with disease activity [16, 31–33]. In addi-
tion to the reduced number of Treg cells, some data suggest an impaired function 
of Treg in SLE like a reduced migratory ability [34]. Also, a defect in T-cell suppres-
sion has been observed in SLE, although this defect seems to be due to effector cell 
resistance rather than a reduced Treg suppressor capacity [35].
A pilot study have shown that circulating CD4+ CD25+ FOXP3 Treg cell num-
bers are markedly reduced in nonpregnant women with SLE compared with healthy 
controls. Treg levels remained depleted in SLE patients when pregnant, while 
those in healthy individuals raised, peaking at 10–12 weeks of gestation. Lower 
quantity of Treg cells was evident regardless of disease activity and medication in 
SLE patients [21]. So, considering the essential role of Treg cells at early stages of 
pregnancy and its implication for immune tolerance, defective functioning and 
decreased number of Treg cells could predispose women with SLE to pregnancy 
complications.
There is little work investigating the presence of Th17 cells in pregnant SLE 
patients, although a study supports an imbalance between Treg and numbers of 
Th17 cells in active SLE. An inverse correlation between Treg/Th17 ratio with sever-
ity of active SLE and anti-DNA antibody levels was reported [36]. Disease flares and 
severe complications of SLE, such a lupus nephritis, seem to be associated with a 
decrease in FoxP3+ Treg cells and an increase in Th17 cells [37, 38]. In a longitudinal 
study that evaluated the changes of serum IL-17 and other cytokines in SLE preg-
nant woman during pregnancy, serum IL-17 concentrations were higher in SLE than 
in controls with no changes during pregnancy [36].
As discussed previously, TGF-β is essential for the differentiation of both Treg 
cells and Th17 cells. In a large cohort study, reduced levels of TGF-β were associated 
with increased SLE activity [39]. Although TGF-β influence in reproduction and 
complications in pregnancy is not clear, a possible role in trophoblast invasion has 
been proposed as low levels of TGF-β in the second trimester of pregnant woman 
have been associated with an increased risk of developing preeclampsia [16]. 
Clearly, more studies are needed to understand the role of Treg/Th17 imbalance 
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in SLE pregnancies and its possible implications in the risk of maternal-fetal 
complications.
As mentioned above, pregnancy induces important hormonal changes. Prolactin 
(PRL) levels increase progressively during pregnancy and lactation in order to 
stimulate the synthesis of milk in the mammary glands [42]. Elevated levels of PRL 
have been found in almost one third of SLE patients, and higher levels during the 
second and third trimesters have been associated with clinical activity and poor 
maternal and fetal outcome [40, 41]. On the other hand, the presence of anti-PRL 
autoantibodies in 13.1% of pregnant patients with SLE has been reported. Likewise, 
a lower frequency of maternal and fetal complications in SLE patients than those 
without these antibodies was reported [41].
Therapeutic blockade of PRL with bromocriptine (BRC), a dopamine analog 
that suppresses PRL secretion, has been evaluated to prevent lupus relapses 
during pregnancy and postpartum. A pilot study explored the use of BRC 
between 25 and 35 weeks of gestation in two groups of ten pregnant SLE patients 
each. No patient in BRC group had disease flares, and there were lower adverse 
maternal and fetal outcomes in the treatment group than the group that did not 
receive BRC during pregnancy [42]. More recently, a randomized clinical trial 
evaluated the use of BRC in the postpartum of 76 SLE pregnant women. BRC 
administration for 2 weeks after delivery reduced the disease relapse rate of the 
treatment group [43].
So, results from clinical studies support the contribution of PRL to complica-
tions in pregnant SLE women and a possible role of BRC in the prevention of 
disease relapses during pregnancy and postpartum.
3. Influence of pregnancy in SLE outcomes
The critical immunologic adaptations during pregnancy and postpartum can 
impact maternal autoimmune diseases in several ways. One is triggering the onset 
of an autoimmune disease in postpartum or influencing disease activity of an 
established disease. In this manner, disease response to complex pregnancy changes 
depends on its pathophysiology [2].
As seen before, steroid hormones and cytokine profiles differ in SLE patients 
compared with healthy women during pregnancy leading to a dysregulation of 
the balance between cell-mediated and humoral immune responses, which could 
explain the variability of the SLE course during gestation [44]. Since SLE is con-
sidered mainly a Th2-mediated disease, pregnancy-related changes could trigger 
disease onset or increase the risk of disease exacerbations during this period [45]. 
Also, hormones such as estrogen and prolactin could play a role in amplifying the 
inflammatory effect that characterizes lupus relapses. In murine models, increasing 
doses of estrogen, like those seen in pregnancy, promotes physiological and immu-
nological changes associated with increased lupus activity [46].
3.1 Lupus activity and its relationship with pregnancy
Whether SLE activity increases during pregnancy or not has been previously 
debated in the literature. The majority of prospective studies in SLE pregnancies 
have shown that the risk of disease flare is higher during pregnancy, although some 
discrepancies exist due to heterogeneity of lupus flare definition and tools used 
to assess lupus activity [2]. Newer studies using validated instruments for disease 
activity assessment have found a two–threefold increase in SLE activity during 
pregnancy [47, 48]. Even though SLE flares occur at any time during pregnancy, 
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most of these flares are considered mild to moderate in severity and may include 
renal, hematological, and musculoskeletal systems. Likewise, previous organ 
involvement predicts the same type of condition during pregnancy, particularly in 
the case of renal, hematological, and cutaneous activity [36].
Disease activity at conception and in the previous 6 months, both clinical and 
serological, is a key predictor not only for obstetrical complications but also of 
SLE flares during pregnancy. Prospective studies of pregnant lupus patients have 
reported some risk factors for SLE activity during pregnancy: a high number of 
relapses prior to pregnancy, high SLEDAI index before pregnancy, and preconcep-
tion SLE activity [46, 49]. In fact, the risk of severe lupus flare is increased about 
seven times in patients with active SLE at conception [50]. Moreover, SLE disease 
activity immediately prior to pregnancy also impacts on damage accrual after 
pregnancy [51].
Besides disease activity at and before conception, several predictors for 
flares in pregnant patients have been described. A prospective evaluation of 254 
patients found that discontinuation of hydroxychloroquine (HCQ ) was associated 
with a higher degree of lupus activity (measured by SLEDAI) during pregnancy 
as well as an increased rate of flare during this period. On the contrary, women 
who continued taking HCQ required lower average dose of prednisone during 
pregnancy [52].
In addition, primigravity seems to influence the risk of lupus flares during 
pregnancy. A retrospective analysis of 124 pregnancies found that the first preg-
nancy in SLE women was associated with an increased risk of relapse at any level, 
particularly in the kidney [53].
On the other side, SLE activity during or prior to pregnancy is associ-
ated with several maternal and fetal complications such as fetal loss, preterm 
birth, intrauterine growth retardation (IUGR), and hypertensive complica-
tions. Previous renal disease is also a risk factor for obstetric complications 
like PE, fetal loss, IUGR, and premature birth. Therefore, early identification 
and prompt treatment in pregnant women with lupus activity are essential to 
improve pregnancy outcomes [49]. However, recognition and management 
of disease flares during pregnancy can be challenging due to the physiologi-
cal changes that occur during this period, which can overlap with clinical and 
laboratory features of active SLE [46]. For this reason, clinical data and labora-
tory findings in pregnant patients with SLE should be interpreted with caution. 
Thrombocytopenia, mild anemia, and increased erythrocyte sedimentation rate 
(ESR) often occur during normal pregnancy. In addition, complement levels 
are less reliable to identify or support the suspicion of disease activity due to 
its physiological increase during pregnancy, although a decrease in C3 and C4 
titers as well as an increase in anti-DNA antibodies may be useful to differentiate 
complications such as preeclampsia and SLE activity.
3.2 Lupus nephritis, pregnancy, and hypertensive complications
Lupus nephritis is among the findings that most often induces increased mor-
bidity and mortality during pregnancy. Indeed, lupus nephritis, especially active at 
the time of conception, has been associated with an increased risk of relapse during 
pregnancy. A higher risk of SLE activity has been reported, particularly renal flares, 
in pregnant patients with previous nephritis compared to those patients without 
history of renal involvement [54]. However, a recent prospective multicenter study 
did not find an increased risk of renal flares during pregnancy in patients with a 
history of previous renal activity and clinically active lupus nephritis at concep-
tion. Instead, history of renal flares before pregnancy predicted hypertensive 
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complications such as preeclampsia (PE) [55]. A meta-analysis of 37 studies 
reported lupus nephritis flare in 16% of pregnant lupus patients and confirmed the 
association of lupus nephritis at conception with an increased risk of hypertension 
during gestation. Adverse outcomes in pregnant patients with lupus nephritis were 
also related to hypertension and presence of antiphospholipid antibodies [56]. 
Moreover, the onset of PE seems to occur at earlier weeks of gestation in lupus 
nephritis patients compared to SLE patients without renal involvement [57].
Preeclampsia is a syndrome unique to pregnancy that manifests with hyperten-
sion and proteinuria and resolves following delivery. Besides classical risk factors 
in general population, diseases that promote endothelial dysfunction including 
SLE increase the risk of preeclampsia. Among lupus pregnancy cohorts, the rate of 
preeclampsia ranges varies widely. Whereas a meta-analysis of lupus pregnancies 
reports a preeclampsia rate of 7.8%, other studies suggest that it can be twice as 
high, particularly in women with nephritis [29, 56]. Dysfunctional angiogenesis 
leading to an impair in placental development has been implicated in pathogenesis 
of preeclampsia. Several markers in maternal serum like VEGF, placental growth 
factor (PlGF), and soluble fms-like tyrosine kinase (sFlt-1) have been found to 
be predictive of preeclampsia in lupus patients. Lower than expected levels of 
Features Preeclampsia Lupus nephritis
Timing in pregnancy >20 weeks of gestation Throughout gestation and 
postpartum
Physical findings
- Hypertension  
(BP >140/90)
Present Present
- Edema Present Present
- RUQ tenderness May be present Absent
- Visual symptoms/seizures Present with severe features Absent
Lupus activity
- Fever Absent Present/absent
- Malar rash Absent Present/absent
- Arthralgias/arthritis Absent Present/absent
- Oral ulcers Absent Present/absent
Laboratory findings
- Proteinuria Present >20 weeks Present <20 weeks
- Active urinary sediment Absent Present
- Increased creatinine Usually normal May be increased
- Complement Normal/increased Normal/decreased
- Anti-dsDNA Absent May be increased
- aPL antibodies Absent May be present
- Abnormal LFTs Present with severe features Absent
Renal biopsy findings Endothelial cell swelling, loss of 
fenestrations, occluded capillary lumen, 
rare thrombi
WHO class II to class VI 
lupus nephritis
Thrombi and vascular 
changes with aPL
Data from [60, 61]. BP, blood pressure; RUQ , right upper quadrant; anti-dsDNA, anti-double-stranded DNA; aPL, 
antiphospholipids; LFTs, liver function tests
Table 1. 
Clinical, laboratory, and renal biopsy findings in preeclampsia and lupus nephritis during pregnancy.
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proangiogenic factors VEGF and PlGF and high levels of antiangiogenic factor 
sFlt-1 seem to reflect poor placental perfusion and impaired angiogenesis in the 
rapidly growing placenta [29].
Similar to what happens in lupus flares during pregnancy, distinguish clinical 
indicators of lupus nephritis from pregnancy physiological features, and those 
related preeclampsia can be a complex task. In the first trimester of pregnancy, 
maternal systemic circulation suffers remarkable physiological vasodilation 
conditioned by relaxin, a hormone produced by the corpus luteum. As a result 
of systemic vasodilation, glomerular filtration rate (GFR) elevates, and serum 
creatinine consequently diminishes making it more difficult to identify a renal 
compromise in a timely manner [58]. Urine protein excretion is also increased 
during pregnancy, so isolated elevation of proteinuria is not necessarily indicative 
of active nephritis [7].
Besides physiological changes induced by pregnancy, PE and LN share some 
clinical and laboratory features like hypertension, proteinuria, and edema, making 
it difficult to distinguish between the two entities. This distinction is critical since 
management differs significantly; while LN requires immunosuppressive treat-
ment, in severe PE delivery may be indicated. A detailed evaluation of biomarkers 
of SLE activity as anti-dsDNA, the low level of complement, active urine sediment 
(red cells, white cells, and cellular casts), and the presence of extrarenal SLE 
manifestations may be helpful in the differential diagnosis. In contrast, in pregnant 
women with a gestational age greater than 22 weeks and absence of sign of SLE 
activity, the diagnosis of PE is very likely [59].
Clinical, laboratory, and renal biopsy features present in PE and LN are shown 
in Table 1.
4. Impact of SLE on pregnancy outcomes
Despite diagnostic and therapeutic advances, pregnancies in SLE patients are 
still considered a high-risk condition due to an elevated risk of major obstetric and 
neonatal complications. A population-based study from 2000 to 2003 found that 
maternal mortality was 20-fold higher among women with SLE. The risk for serious 
medical and pregnancy complications during pregnancy was also three- to seven-
fold higher for SLE women than the general population [62].
In recent years, outcomes during pregnancy in patients with SLE related to pre-
conceptional counseling, close monitoring during pregnancy, and postpartum and 
multidisciplinary management have improved [63]. However, according to a recent 
meta-analysis comparing maternal and fetal outcomes of women with and without 
SLE, adverse outcomes such as spontaneous abortion (RR, 1.51), PE (RR, 1.91), 
thromboembolic disease (RR, 11.29), and preterm birth (RR, 3.05) are still more 
frequent in pregnancies of women with SLE [64]. Additionally, it has been estimated 
that women with SLE have fewer live births than the general population [65].
In the last two decades, the rate of fetal losses has declined from 43% in the years 
1960–1965 to 17% in the period 2000-2003 [66]. Most recent studies reported a 
pregnancy loss rate of 10–25% in women with SLE [67]. In addition to risk factors 
associated with pregnancy losses in the general population, such as chromosomal 
and anatomical abnormalities, specific factors associated with SLE have to be 
Considered, including thrombocytopenia, antiphospholipid antibody (aPL) 
positivity or antiphospholipid syndrome (APS), lupus nephritis, and high SLE 
disease activity [68]. Both low complement and presence of anti-DNA in the second 
trimester, regardless of clinical activity, have also been associated with a higher rate 
of fetal loss and preterm delivery [69].
Lupus
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4.1 Antiphospholipid antibodies and pregnancy
The presence of antiphospholipid syndrome (APS) is one of the most important 
causes for pregnancy loss in women with SLE, manifesting a recurrent pregnancy loss, 
fetal loss, or stillbirth (pregnancy loss after 20 weeks of gestation) [29]. In addition to 
recurrent pregnancy loss, APS predisposes pregnant women to late gestational com-
plications associated with impaired placental function, such as PE and fetal growth 
restriction. Serious complications have been reported in up to 12% of pregnancies in 
lupus patients. Interestingly, adverse outcomes in pregnancies of SLE women with 
aPL antibodies can present even during disease remission or mild activity [50].
Antiphospholipid antibodies target the placenta by binding β2 glycoprotein I 
(β2GPI) constitutively expressed on trophoblast cell surface, perturbing the secre-
tion of trophoblast angiogenic factors in the first trimester of gestation and favoring 
adverse outcomes [70].
The prevalence of aPL antibodies in patients with SLE is variable and depends 
on the type of antibodies and isotype. A prevalence of 12–44% of anticardiolipin 
antibodies (aCL), 15–34% for lupus anticoagulant (LA), and 10–19% for anti-β2 
glycoprotein I (aβ2GPI) has been reported [71], although prevalence of aPL could 
be underestimated due to immunosuppressive treatment. A higher frequency 
of thrombosis and pregnancy loss in SLE-associated APS (secondary APS) than 
in primary APS has been reported. Moreover, in the Hopkins lupus cohort, the 
diagnosis of secondary APS led to a threefold increase in pregnancy loss, especially 
after 20 weeks of gestation and was an independent risk factor for further preg-
nancy losses [68].
The association of aPL with adverse pregnancy outcomes (APOs) is variable 
between different aPL antibodies. Particular serological profiles have been defined 
as “high-risk profiles” because of its stronger association with APOs. Lupus 
anticoagulant rather than aCL has been identified as the primary predictor of 
APOs [72]. In the PROMISSE study, a large-scale multicenter prospective study of 
pregnant women with aPL and/or underlying stable SLE, a higher rate of APOs in 
pregnant patients with aPL (43.8%) compared to 15.4% of patients without aPL 
was observed, while poor pregnancy outcome was observed mainly in LA-positive 
patients. The presence of LA was identified as a baseline independent predictor of 
APOs (OR 8.32), while no other aPL antibody independently predicted APO [73]. 
The EUROAPS registry also reported that the presence of LA, isolated or in combi-
nation with aCL and/or aβ2GPI, was the strongest marker related to poor obstetric 
outcomes [74].
Regarding treatment, there is no current evidence that the management of preg-
nancy should be different in SLE-associated APS than in primary APS. Actually, 
treatment of pregnant patients with aPL will depend on the risk profile and history 
of adverse obstetric events or previous thrombosis. According to this risk, they 
can be classified into three groups: (a) presence of aPL antibodies in the absence 
of obstetric or thrombotic events, (b) high-risk profile (LA or triple positivity) or 
adverse obstetric events, and (c) aPL antibodies and previous thrombosis.
Although increased lupus activity does seem to not increase the risk for mis-
carriage, stillbirth rate is threefold higher [53]. Additionally, the timing of lupus 
activity seems to impact the pregnancy loss rate, with activity early in pregnancy 
being the most dangerous [68].
4.2 Antibodies anti-SSA/Ro and anti-SSB/La and neonatal lupus
Pregnancies exposed to anti-SSA/Ro and anti-SSB/La have an increased risk 
of developing neonatal lupus (NL), a passively acquired autoimmune disease 
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mediated by maternal antibodies. There are two main forms of NL: NL erythema-
tosus (NLE) and congenital heart block (CHB). Other less frequent forms include 
hepatic and hematologic. NLE occurs in 5% of children born to women with 
anti-Ro/SSA or anti-La antibodies. It usually presents within the first 2 weeks of life 
as erythematous geographical lesions in light-exposed areas, resembling subacute 
cutaneous lupus. Rash resolves within 6–8 months of life as the maternal antibod-
ies are cleared, without leaving residual scarring [75]. CHB is a more serious form 
of NL, affecting 1–2% of newborns of anti-Ro-positive women and a recurrence 
rate in subsequent pregnancies up to 16–20%. Incomplete forms of CHB have been 
described, including first-degree heart block that can progress during childhood. 
Permanent pacemaker will be needed in most children with CHB, and up to 20% 
may die in the perinatal period [76].
Starting from the second trimester, maternal IgG antibodies are actively 
transferred via the placental FcRn receptor to the fetus. Although the precise 
mechanism of injury is not fully known, one hypothesis considers a direct effect 
of anti-SSA/Ro and/or anti-SSB/La antibodies by binding to fetal cardiac tissue 
and altering cardiocyte function. In the case of anti-SSA/Ro antibodies, they can 
bind cross-reactive epitopes on calcium-regulating molecules such as ion chan-
nels, inducing disturbances in calcium homeostasis and signal electrogenesis 
at the atrioventricular node. A demonstration that anti-SSA/Ro antibodies are 
arrhythmogenic and inhibit inward calcium fluxes across cell membranes sup-
ports this hypothesis [77].
Another hypothesis raise that intracellular anti-SSA/Ro and SSB/La antigens 
translocate to the surface of cardiomyocytes undergoing apoptosis during physi-
ological remodeling and thus become accessible to extracellular antibody. This 
allows the formation of pathogenic antibody-apoptotic cell immune complexes that 
promote a pro-inflammatory and profibrotic response [78]. In vitro studies support 
a protective role of β2GPI by preventing opsonization of apoptotic cardiomyocytes 
by maternal anti-Ro60 IgG [79].
CHB is usually preceded by lesser degrees of conduction delays which may be 
reversed with early treatment. Given that the majority of conduction abnormalities 
develop between 18 and 24 weeks of gestation, several tools for early detection of 
lesser degrees of heart block are available, including fetal Doppler echocardiog-
raphy, fetal kinetocardiogram, and transabdominal fetal echocardiography. Close 
monitoring of anti-SSA/Ro-positive pregnant women with weekly fetal Doppler 
echocardiography between 16 and 26 weeks of gestation and biweekly thereafter is 
highly recommended [61]. This enables assessment of atrial and ventricular rates, 
cardiac anatomy and function, and the presence or absence of hydrops. Urgent 
referral to a fetal medicine unit or fetal cardiology service is advised if a low fetal 
heart rate (<110 bpm) is detected. An increased risk of hydrops and death is present 
if the rate is <55 bpm [76].
Although fetal echocardiogram is the most commonly used modality, it may 
underestimate pathological findings of NL, so recently other biomarkers for early 
detection of heart disease and to monitor severity and progression of cardiac LN 
have been suggested, such as NT-proBNP in amniotic fluid [80].
Different strategies have been evaluated for CHB associated with anti-Ro and/
or anti-La antibodies. Prenatal therapy with fluorinated steroids like dexametha-
sone in mothers of fetuses with incomplete heart block is currently used; however, 
its role has been questioned since published data are discordant regarding its 
efficacy. A multiracial/ethnic US-based registry of cardiac neonatal lupus demon-
strated that fluorinated steroids do not prevent heart block progression or death in 
cases with isolated heart block and without evidence of extranodal disease [81].  
In a more recent study, the use of fluorinated steroids was not associated with 
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complete heart block regression or an increase in survival [82]. Therefore, the deci-
sion to administer this type of steroid, usually at high doses (at least dexametha-
sone 4 mg daily), should be weighed against the potential risk of adverse effects on 
the fetus and the mother [78].
Preventive management of anti-SSA/Ro- and/or anti-La/SSB-positive preg-
nant women is under investigation. Hydroxychloroquine administration during 
pregnancy has been associated with a decrease of recurrent NL [83]. On the 
other hand, recent studies failed to demonstrate efficacy of monotherapy with 
intravenous immunoglobulin or plasma exchange in reducing the incidence of 
cardiac NL [84, 85].
5. Contraception, fertility, and assisted reproduction in SLE
Contraception is a complex issue and of particular interest in SLE patients to 
prevent unplanned pregnancies during periods of disease activity or potentially 
teratogenic drug exposure. The main concerns about hormonal contraceptive 
methods are disease flares and risk of thromboembolism [86]. The risk of complica-
tions associated with the use of hormonal contraceptives has been evaluated by 
two randomized clinical trials. A first study compared a combined three-phase oral 
contraceptive with placebo in 183 patients with SLE. No significant differences in 
the number of disease flares between both groups were observed [87]. A second 
study compared a combined oral contraceptive, a progestogen, and non-medicated 
intrauterine device. Disease activity remained stable during follow-up, and only 
four thrombosis episodes were recorded, two episodes per hormone treatment 
group [88]. However, both studies excluded patients with severely active SLE, his-
tory of previous thrombosis, malignant gynecological neoplasm, acute myocardial 
infarction, and previous hepatopathies and patients actively smoking. Regarding 
aPL antibodies, patients with positivity for these antibodies were excluded in the 
first study, but not in the second trial. According to both studies, combined hor-
monal contraceptives (estrogens plus progestogens or progestins alone) are safe 
in patients with stable SLE in the absence of aPL, without increasing the risk of 
disease flares of thrombotic events.
Fertility is a relevant topic in SLE patients due to predominance of female 
gender and reproductive age. The reproductive issue in SLE women does not result 
from an increase in primary fertility rate but from an increase in the number of 
fetal losses and use of drugs related to infertility. Cyclophosphamide (CYC) has 
been associated with ovarian reserve depletion by inducing apoptosis of oocytes 
and granulosa somatic cells, with the consequent premature ovarian failure in 
a dose- and age-dependent manner. Although the exact incidence of secondary 
ovarian failure due to CYC is not clear, it may vary between 11 and 59%, and a 
higher risk is observed in women older than 30 years [89]. Simultaneous adminis-
tration of GnRH agonist has been suggested to minimize the gonadotoxic effect of 
CYC. Other disease-modifying rheumatic drugs (DMARDs) such as mycopheno-
late mofetil, cyclosporine, or tacrolimus have not been associated with infertility in 
lupus patients [90].
On the other hand, it has recently been suggested that SLE per se has a nega-
tive effect on ovarian function and reserve, regardless of the disease activity and 
use of gonadotoxic immunosuppressive therapies. A study that measured levels of 
anti-Müllerian hormone (AMH), a marker of ovarian reserve, in lupus patients and 
healthy controls found lower levels of AMH in the first group, with no correlation 
between disease activity and duration [91].
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The role of aPL antibodies as a cause of infertility is controversial, as previous 
retrospective studies have suggested an association between aPL antibodies and 
infertility. However, two recent studies have not demonstrated a higher prevalence 
of these antibodies in women with infertility or a correlation with the type of 
infertility [92, 93].
A strategy to overcome the difficulties of achieving a successful pregnancy is the 
use of assisted reproduction technologies (ARTs), which includes ovarian stimulation, 
oocyte retrieval, in vitro fertilization (IVF), and transfer of the embryo to the uterus 
[94]. Many stimulation protocols are available, but ovarian stimulation with human 
chorionic gonadotropin (hCG) is the most frequently applied. These hormones deter-
mine an estrogenic peak in order to stimulate the growth of multiple follicles, which 
may increase the risk of multiple pregnancy, preterm birth, and ovarian hyperstimula-
tion syndrome, but the main concern rises around the risk of disease exacerbation or 
maternal complications. Although the hormonal stimulation could theoretically trigger 
a disease flare or the onset of thrombosis in patients with aPL antibodies, recent studies 
have shown that they can be safe and have a low probability of SLE flare [94, 95].
A relevant issue with the use of ARTs is the incidence of thrombotic events. 
During ovarian stimulation, several changes in coagulation have been described 
including an increase in fibrinogen, von Willebrand factor, and platelets and 
decrease in antithrombin III and fibrinolytic activity. These changes may induce a 
state of relative hypercoagulability. However, the absolute risk of thrombosis during 
ovarian stimulation is low due to the predominant use of estradiol (E2) and short 
time of stimulation. The observed incidence is quite low and related to ovarian 
hyperstimulation syndrome. A systematic review identified as risk factors for 
thromboembolic complications advanced age (>35 years) and hereditary thrombo-
philias, while SLE and APS were not independent risk factors [96].
Regarding the efficacy of ART, the success rate varies from 16 to 31% in women 
with SLE, similar to the general population [48]. The role of aPL has been examined 
by previous retrospective studies that suggested a relationship between aPL positiv-
ity, infertility, and multiple failures of ART procedures. However, recent evidence 
does not support this since the presence of aPL antibodies has not been identified as 
a predictor of failure during the use of ART [97]. In a prospective study of 101 infer-
tile women with at least three unsuccessful IVF attempts, no association was found 
between aPL positivity and success rate [98].
Despite the lack of studies evaluating the risks and benefits of different ovarian 
stimulation protocols, it is suggested to avoid high serum concentration of estradiol. 
In the case of anovulation, ovarian induction with clomiphene citrate represents 
the first choice. In treatment failure, pulsatile administration of GnRH over the use 
of gonadotropins is preferred since the latter does not confer the risk of ovarian 
hyperstimulation syndrome [91].
The period of the highest risk is not ovarian stimulation but pregnancy due to 
elevated rates of fetal and maternal complication, so the main reason for rejecting 
ART in women with SLE is foremost the risk of obstetric and maternal adverse out-
comes. ART is safe in patients with stable SLE; however, its use is not recommended 
in patients with active SLE, uncontrolled hypertension, chronic kidney disease, 
severe valve disease, or severe thromboembolic events [48].
6. Algorithm in women with SLE
An algorithm proposal to approach women with SLE of childbearing age is 
presented in Figure 1.
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7. Conclusions
Pregnancy induces immunologic and hormonal adaptations on a pregnant 
woman to permit maternal tolerance to the fetus. The balance between Th17 cells 
and Treg cells seems critical to pregnancy outcomes, although its possible implica-
tion in maternal-fetal complications in SLE woman is not completely understood.
The relationship between SLE and pregnancy is close and bidirectional; active 
disease is associated with the increased risk of adverse pregnancy outcomes and 
pregnancy changes which impact on maternal disease triggering flares during  
this period.
Besides disease activity, immunologic factors related to SLE such as aPL and 
anti-SSA/Ro antibodies can also influence obstetric and neonatal outcomes. The 
Figure 1. 
Approach to pregnant woman with SLE. Data from [76, 99]. aPL, antiphospholipid; LMWH, low-molecular-
weight heparin; LDA, low-dose aspirin; IUGR, intrauterine growth restriction.
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presence of aPL antibodies is one of the most important risk factors for pregnancy 
loss and late gestational complications in women with SLE. Treatment of preg-
nant patients with aPL will depend on the risk profile and history of obstetric or 
thrombotic events. Anti-SSA/Ro antibodies are related to neonatal lupus due to 
active transplacental transfer of these antibodies possibly causing direct injury to 
the cardiac conduction system manifesting as congenital heart block. Fetal Doppler 
echocardiographic monitoring between 16 and 26 weeks of gestation is highly 
recommended in pregnant women with anti-SSA/Ro for early detection of heart 
conduction delays.
Combined hormonal contraceptives are safe in women with stable SLE in the 
absence of aPL, without an increasing risk of disease flares or thrombotic events. 
Fertility in women with lupus can be affected not only by exposure to drugs related 
to infertility but also by SLE per se.
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